Gilead Sciences Inc: (NASD: GILD)

$50.60

-1.34 (-2.58%)

Volume 6,405,607

Jun 19 04:00 PM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		50.57 - 52.05
	
		52wk Low - High
		24.80 - 58.07
	
		Previous Close
		51.94
	
		Avg. Volume
		10,126,392
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		79.23 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.51
	
		P/E (F1)
		27.41
	
		Current Year Est.
		1.89
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		112 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/6/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            27.41
                        
                            PEG Ratio
                            1.04
                        
                            Current Year Est.
                            1.89
                        
                            Current Quarter Estimate
                            0.47
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            07-25-2013
                        
                            EPS Last Year
                            1.88
                        
                            Expected Earnings Growth
                            26.33%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.   
Full GILD Company Report

 Analyst Report on GILD

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
GILD Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.47	0.46	1.90	2.79
Number of Estimates	2	2	2	2
Low Estimate	0.46	0.44	1.83	2.36
High Estimate	0.47	0.48	1.96	NA
Year Ago EPS	0.47	0.47	1.73	1.90
EPS Growth	-1.06%	-3.16%	9.54%	47.23%

More GILD Estimates

Average Earnings Estimates for GILD

EPS Growth for GILD

Industry Analysis

Name	Symbol	Previous Close
GILEAD SCIENCES	GILD	51.94
AETERNA ZENTARS	AEZS	1.90
BIOGEN IDEC INC	BIIB	210.80
MYRIAD GENETICS	MYGN	26.44
PROTALIX BIOTHR	PLX	5.08
ADDEX THERA LTD	ADDXF	3.95
AFFYMAX INC	AFFY	1.07
ALEXION PHARMA	ALXN	92.39
ALNYLAM PHARMA	ALNY	29.99
ANTHERA PHARMA	ANTH	0.58

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Gilead Presents Idelalisib Data

Jun 19, 2013

3 Impressive Biotech ETFs Crushing the Market

Jun 11, 2013

Priority Review for Gilead Drug

Jun 10, 2013

Stock Market News for June 3, 2013

Jun 03, 2013

Gilead's Stribild Approved in the EU

May 29, 2013

Gilead's Sofosbuvir under European Review

May 22, 2013

Pipeline Progress at Gilead

May 16, 2013

Stock Market News for May 14, 2013

May 14, 2013

More GILD Zacks Commentary

Financials

EPS TTM	1.88
Sales	9,703
Net Income	2,872
Price/Earnings	27.70
Price/Book	7.62
Price/Cash Flow	26.10
Price/Sales	7.96

More GILD Financials

News

3 Blood Cancer Drug Hopefuls in the Spotlight - TheMotleyFool

Jun 19, 2013

Myelofibrosis - Pipeline Review, H1 2013 - M2

Jun 19, 2013

SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 2.58% Loss - Comtex Smartrend(R)

Jun 19, 2013

Watch for Gilead Sciences to Potentially Rebound After Falling 2.58% Yesterday - Comtex Smartrend(R)

Jun 19, 2013

Gilead Sciences receives FDA priority review for hepatitis C virus drug - Datamonitor

Jun 18, 2013

Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics - Pr Newswire

Jun 18, 2013

The Best Healthcare Bet - TheMotleyFool

Jun 18, 2013

CytoDyn Inc. Appoints Anthony D. Caracciolo as Chairman of the Board of Directors - Businesswire

Jun 17, 2013

See All News Stories on GILD

Broker Recommendations

Current ABR	1.27
ABR (Last Week)	1.27
# of recs in ABR	22
Average Target Price	59.78
Industry Rank by ABR	112 out of 265
Rank in Industry	132 out of 154

More GILD Broker Recommendations

Day Low - High	50.57 - 52.05
52wk Low - High	24.80 - 58.07
Previous Close	51.94
Avg. Volume	10,126,392
Industry	MED-BIOMED/GENE
Market Cap	79.23 B
Div - Yield	0.00 - 0.00
Beta	0.51
P/E (F1)	27.41
Current Year Est.	1.89
Quarterly Earnings ESP	NA

P/E (F1)	27.41
PEG Ratio	1.04
Current Year Est.	1.89
Current Quarter Estimate	0.47
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	07-25-2013
EPS Last Year	1.88
Expected Earnings Growth	26.33%

Username: Password:

Remember me [?]

Gilead Sciences Inc: (NASD: GILD)

$50.60

-1.34 (-2.58%)

Volume 6,405,607

Jun 19 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations